AstraZeneca

Serum Institute of India (SII), which has partnered with Novavax, Inc (NASDAQ: NVAX) and AstraZeneca Plc (NYSE: AZN) for trials in India, believes the latter’s COVID-19 vaccine is “a very good one.” What Happened: SII Chief Executive Adar Poonawalla praised the efficiency of...

AstraZeneca HQ and research center in Cambridge, United Kingdom Benzinga has examined the prospects or many investor favorite stocks over the past week. The bullish calls in the holiday-shortened week included old-school and newer consumer favorites. A COVID-19 vaccine contender and a casino...

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) were the first to deliver good news regarding the efficiency of their coronavirus vaccine candidate. Moderna Inc (NASDAQ: MRNA) had its turn last week delivering even better news with U.S. stocks hitting a new record. This Monday,...

This weekend's Barron's cover offers a low-risk strategy for investors optimistic about an ecomomic recovery. Other featured articles discuss what a COVID-19 vaccine would mean for the stock market and how it could shake up the pharmaceutical industry. Also, the prospects for semiconductor...

  This weekend's Barron's examines why the merger frenzy among chipmakers has not impressed investors. Other featured articles discuss stock picks for any presidential outcome, how health insurers perform after elections, and the good, bad and odd of big tech earnings. Also, the...

The Past Week, In A Nutshell What Happened: Last week ended negative alongside mixed messaging on stimulus. Remember This: “Markets have come a long way since the March lows, but we believe there may be more room for stocks to run,” said Jeff Buchbinder, Equity Strategist for LPL...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Both bullish and bearish calls in coronavirus vaccine contenders were seen this week. Social media platforms were represented in both categories as well. September has a reputation as a harsh month for the...

Besides saving lives and the global economy, we are expecting three things from the upcoming COVID-19 vaccine: safety, immunogenicity and efficacy. But we never had a 100 percent efficacy when it comes to respiratory viruses, so anything between 50 and 100% will be the best we've got as the WHO...

The Past Week, In A Nutshell What Happened: Last week ended negative on relative weakness in the technology sector. Remember This: “While valuations have hinted to overstretched markets in the past, it’s tough to say where stocks should be trading right now. We just witnessed the...

Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of news flow on the coronavirus vaccine front. Even as nine vaccine makers released a pledge to put safety first,...

AstraZeneca plc (NYSE: AZN) can heave a sigh of relief following resumption of its coronavirus vaccine study that was voluntarily paused by the company. What Happened: The U.K. pharma giant said U.K. regulatory agency, the Medicines Health Regulatory Authority (MHRA) has given its...

Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included a second-tier telecom and a fast-casual restaurant leader. Bearish calls included beleaguered health care giant and an international bank. The third-quarter earnings reporting season...

Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...